Background. Isolated limb infusion (ILI) is a limb-preserving treatment for in-transit extremity melanoma. The benefit of resecting residual disease after ILI is unclear. Methods. A multi-institutional experience was analyzed comparing patients who underwent ILI plus resection of residual disease (ILI ? RES) versus ILI-alone. Results. A total of 176 patients were included, 154 with ILI-alone and 22 with ILI ? RES. There were no differences between the groups with respect to gender, age, extremity affected, or time from diagnosis to ILI. All surgical resections were performed as an outpatient procedure, separate from the ILI. Within the ILI ? RES group, 15 (68 %) had a partial response (PR), 2 (9 %) stable disease (SD), and 5 (23 %) progressive disease (PD). The ILI-alone group had 52 (34 %) CR, 30 (19 %) PR, 15 (10 %) SD, and 46 (30 %) PD. Eleven (7 %) ILI-alone patients did not have 3-month response available for review. Evaluating overall survival (OS) from date of ILI, the ILI-alone group had a median OS of 30.9 months, whereas the ILI ? RES group had not reached median OS, p = 0.304. Although the ILI ? RES group had a slightly longer disease-free survival (DFS) compared to those with a CR after ILI-alone (12.4 vs. 9.6), this was not statistically significant, p = 0.978. Within the ILI ? RES group, those with an initial PR after ILI had improved DFS versus those with SD or PD after ILI, p \ 0.0001.
Melanoma represents the fifth and sixth most common cancer in the United States in men and women, respectively, with an incidence that has risen over the last decade. 1 Although melanoma accounts for\5 % of skin cancer, it accounts for the majority of skin cancer-related deaths. 1 In-transit disease from extremity melanoma is currently classified as stage IIIB or IIIC disease, with 5-year survival rates of 59 and 40 %. 2, 3 Although the risk of disease relapse is high in these advancedstage patients, 71 % for stage IIIB and 85 % for IIIC disease, often the recurrence is local or occurs in an in-transit fashion (30 and 22 % for stage IIIB and IIIC, respectively). 4 Isolated limb infusion (ILI) is a minimally invasive technique utilized to treat in-transit melanoma of the extremity. First modified from the isolated limb perfusion (ILP) by Thompson et al. in the 1990s, experience with utilizing ILI as a regional control technique has been quickly growing. 5 Although studies have typically been small in size with short-term follow-up, the results have been encouraging, with limb salvage achieved in up to 86 %. 6 A 3-month complete response (CR) in the limb is observed in up to 46 % of patients, with duration of response lasting 3 years or longer. 7, 8 Although ILP has been considered superior to ILI in terms of overall response rate (ORR) and durability of response, ILP is associated with a greater risk of limb loss and is associated with higher toxicity. [9] [10] [11] [12] [13] Overall survival (OS) of patients who achieve a complete response (CR) with ILI is similar to OS observed in those with a CR after ILP. 7 However, ILI is associated with less morbidity than ILP and is considered as a first-line regional therapy at several institutions for intransit melanoma, including the authors. 7, 11, 12 Use of ILI in attempt to downstage or control the burden of disease in a limb before surgical resection has not yet been qualified. In this study, we evaluate the impact of surgical resection of remaining disease after ILI, comparing overall and disease-free outcomes with ILI-alone.
PATIENTS AND METHODS
After institutional review board approval, a retrospective review was conducted from the databases maintained at Moffitt Cancer Center and Duke University Medical Center. From 2004 to 2011, patients with in-transit, stage IIIB or IIIC melanoma, who were treated with isolated limb infusion and subsequent resection of residual or persistent disease (ILI ? RES) were included in this analysis. This cohort was compared with contemporaneous patients who underwent ILI-alone. Demographic features and operative parameters were recorded and compared between the ILI-alone and ILI ? RES group. Tumor burden was classified as low or high. High burden of disease was defined as 10 or more lesions without any single lesion greater than 1 cm or any single lesion 3 cm in diameter or larger. Tumor burden after ILI was not possible to retrospectively collect; therefore, response to ILI or ILI ? RES was not analyzed according to disease burden after ILI.
All ILIs were performed as previously described from both Duke University Medical Center and Moffitt Cancer Center. 12, 14 Briefly, percutaneous catheters were placed by Interventional Radiology under fluoroscopic guidance to the affected limb. The limb was externally warmed to 37°C. Under tourniquet occlusion, melphalan and actinomycin D were then circulated for 30 minutes. The limb was washed out with saline before tourniquet release. The majority (n = 155, 86 %) had dose-correction of Melphalan for ideal body weight.
Three-month response was determined by clinical assessment with physical examination and positron emission tomography (PET) imaging. Patients were considered to have a complete response (CR) if no evidence of disease was present, partial response (PR) as a C30 % reduction in disease burden, stable disease (SD) if no change was evident, and progressive disease (PD) if tumor burden had increased. Patients with persistent disease, deemed surgically resectable, were offered resection to render them clinically disease-free (NED). Patients who achieved a CR at 3 months after ILI who then recurred and underwent surgical resection were excluded from this analysis.
All surgical resections were performed as outpatient procedures. The decision to perform a resection was determined by the surgeon and was generally considered for localized lesion(s) that could be resected primarily without causing significant morbidity such as disfigurement or dysfunction to the extremity. Patients with significant progression of their disease were generally not considered for local resection, as the tumor response suggested resistance to regionally delivered chemotherapy and were considered high-risk for systemic spread. Several patients were offered palliative resection of residual disease after ILI, for symptoms such as severe pain or bleeding. Only patients with residual disease that could be resected so that no remaining disease was evident in the extremity were included in this analysis.
All statistical analyses were performed using SAS (version 9.2, SAS Institute Inc., Cary, NC), with significance considered when the two-sided p-value was B0.05. Categorical variables were compared using Fisher's exact tests; continuous variables were compared using Wilcoxon rank-sum tests, and Kaplan Meier and log rank tests used for survival analyses. Overall survival was defined as time from date of ILI to date of last follow-up or death from any cause. To compare disease-free survival (DFS) between cohorts, only those patients who achieved a CR at 3 months were compared to the ILI ? RES group. Disease-free survival was determined as time from date of ILI (ILIalone patients) or date of surgical resection (ILI ? RES) to date of disease recurrence.
RESULTS

Demographics and Perioperative Parameters
176 patients were included in this analysis, 154 ILIalone and 22 ILI ? RES. There was no difference with respect to gender or median age between the ILI-alone and ILI ? RES groups (Table 1) . There was a similar distribution of disease in upper versus lower extremities between groups. Burden of disease was recorded in 164 (93 %); there was no difference in disease burden between groups, p = 0.821 (Table 1) .
With respect to perioperative parameters, median ischemia time was similar between groups, 63 minutes in the ILI-alone group and 68 minutes in the ILI ? RES group, p = 0.77. Serum creatine phosphokinase (CPK) levels were used to monitor systemic toxicity. The CPK peak and the postoperative day when the CPK peak occurred were also similar between groups, peaking at a median of 584 U/L in the ILI-alone group and 1054 U/L in the ILI ? RES group, p = 0.121, on postoperative day 4 for both groups ( Table 2 ). The Wieberdink toxicity score was used to classify limb toxicity. Although the ILI-alone group had 11 (7 %) patients with a grade 4 Wieberdink toxicity versus 0 (0 %) in the ILI ? RES group, there was no significant difference in overall toxicity between the two groups, p = 0.62. The ILI ? RES group did exhibit a longer median hospital stay, 7 vs. 6 days, p = 0.047 (Table 2) . Because the hospital length of stay was related only to the ILI procedure, it is unclear why the ILI ? RES patients had a 1-day-longer length of stay from their ILI because the ILI and surgical resection were performed in two separate settings.
Three-month Response
At 3-month follow-up after ILI, the ILI ? RES group had 15 (68 %) PR, 2 (9 %) SD, and 5 (23 %) PD. The median time to resection from ILI was 3.3 months for the entire group (range 0.2-11.2 months). 2 months following ILI, the majority (n = 16, 73 %) underwent resection at or after 3-month follow-up. Patients who either had symptomatic disease (i.e., pain or bleeding), or were close to the 3-month follow-up point, were offered resection of disease before the 3-month time point. The ILI-alone group demonstrated 3-month response rates of: 52 (34 %) CR, 30 (19 %) PR, 15 (10 %) SD, and 46 (30 %) PD. Eleven patients (7 %) in this group had unrecorded 3-month clinical response. The median time from melanoma diagnosis to ILI was similar between groups, 25 months for ILIalone vs, 37 months for ILI ? RES, p = 0.222 (Table 3) .
Overall and Disease-free Survival
Median follow-up from ILI for the cohort was 16.6 months (range 0.2-71.2 months). Median OS from time of ILI was 30.9 months in the ILI-alone group; median OS was not reached in the ILI ? RES group. There was no significant difference in OS between the ILI-alone and ILI ? RES groups, p = 0.304 (Fig. 1) . Of those in the ILI-alone group who achieved a 3-month CR, 31 (63 %) developed disease recurrence. In the ILI ? RES group, 13 (59 %) developed disease recurrence, p = 0.795. Although median DFS was longer in the ILI ? RES group (12.4 months vs. 9.6 months for ILI-alone), this was not significant, p = 0.978 (Fig. 1) .
The ILI-alone group was then compared with ILI ? RES according to the 3-month clinical response of ILIalone. Patients with a 3-month CR after ILI-alone had a median OS of 33.7 months; those with a 3-month PR had a median OS of 38.4 months. Although it may appear that there is trend toward worse OS after a CR with ILI, there was no statistical significance between these two groups. The median OS of those achieving a 3-month CR or PR after ILI was similar to patients who underwent ILI ? RES, who did not achieve median OS at the time of this analysis, p = 0.506 (Fig. 2) . Evaluating DFS of those who achieved a CR after ILI-alone, median DFS of the ILI ? RES group who had a 3-month PR was longer over CR with ILI-alone, 15.2 vs. 9.6 months, respectively (Fig. 2) . Those who underwent ILI ? RES who had SD or PD, however, had a shorter median DFS of 3.8 months, p = 0.018 (Fig. 2) .
Within the ILI ? RES cohort, survival was also compared by the 3-month clinical response after ILI. There was no difference in OS between patients who achieved PR versus SD versus PD, p = 0.135. However, median DFS was significantly improved in patients with a PR at 3-months after ILI compared with patients with SD or PD (15.2 vs. 1.9 vs. 7.0 months, respectively), p \ 0.0001. 
DISCUSSION
Experience with ILI as a regional therapy for in-transit melanoma is growing. One of the larger studies explores the Melanoma Institute Australia (MIA) 14-year experience following 185 patients undergoing ILI, demonstrating an overall response rate (ORR) of 84 %, with a median duration of response of 13 months. Those patients with a CR after ILI had a significantly improved median survival of 22 months vs. 9 months with PR, p = 0.012. 15 Median overall survival for their cohort was 38 months. Those with a CR had significantly improved OS compared to non-CR (53 vs. 25 months, p = 0.005). They concluded that ILI produced outcomes and duration of response comparable to HILP. 15 A recently updated publication by the MIA demonstrated a slightly decreased ORR of 77 % for their more recent ILIs; however, no significant survival differences were observed. 16 The experience in the United States is growing at a rapid pace. Differences in methodology from those in Australia may contribute to the differences in outcome observed so far. In a recent multi-institutional United States experience, ILI was offered as a regional therapy for patients with intransit melanoma, stage IIIB or IIIC; this is contrary to the MIA which reports on ILI inclusive of stage I and II disease as well as planned double or repeat ILI. 14 Additionally, response at our institute and Duke University Medical Center is typically recorded at 3-month follow-up on the basis of both clinical examination and PET imaging, while MIA reports response by two clinical observations \4 weeks apart. 15 An early multi-center U.S. experience of 128 patients reported ORR of 64 %, with 31 % achieving CR. With low toxicity being observed, ILI was considered an acceptable alternative to HILP. 17, 18 A recent study from Duke University Medical Center followed 126 patients who underwent ILI for the first time for melanoma. Although the ORR was low (43 %), CR was achieved in 30 %.
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Median OS for CR was improved at 35 months vs. 15 months for non-CR. 11 Survival after CR from ILI was comparable to CR after HILP. 11 Clearly, obtaining a CR after ILI is an important prognostic indicator for prolonged overall and disease-free survival and offers comparable disease control as a CR with HILP. In a recent study by Sharma et al., exploring patterns of disease recurrence after a CR from ILI, 56 % of patients had developed an in-field recurrence at 3-year follow-up. 19 Of various methods utilized to address recurrences in the limb after ILI, wide local resection was the most commonly used procedure, producing an 8-month duration of response. 19 Although considered somewhat extreme, limb amputation may even be palliative after failed ILI. In a study of 14 patients treated at MIA who had persistent disease or disease recurrence after ILI and underwent limb amputation, an ORR of 71 % was observed with a median duration of response of 7 months. The median time from ILI to amputation was 11 months. 20 Median survival after amputation was 13 months, range 1 to 84 months; however, effective symptom relief was achieved in all patients. 20 Clearly, a role for surgical intervention exists after failed ILI for control of limb disease from melanoma.
The current study found an overall response rate (CR ? PR) of 57 % in the ILI-alone group evaluated at 3 months after ILI. The groups were comparable with respect to demographics, time from diagnosis, and tumor burden. There were no differences observed in the perioperative parameters between groups. Disease-free survival was similar between the ILI-alone group with 3-month CR and the ILI ? RES group, suggesting that surgery with resection to achieve NED may offer the potential of improved disease-free survival. Further analysis demonstrated that the group that had a 3-month PR after ILI and went on to resection demonstrated the best DFS and had a similar median DFS compared to those with a CR after ILI-alone and improved DFS than ILI ? RES with SD or PD. Although no statistically significant OS differences were observed between the ILI-alone group and ILI ? RES, median survival was not reached in the ILI ? RES group. Longer follow-up may demonstrate improved survival in those patients who undergo ILI ? RES.
Surgical resection represents one of many treatment options available for in-field recurrence of extremity melanoma. Repeat ILI has demonstrated similar ORR as initial ILI and is offered to patients with unresectable disease recurrence who previously demonstrated a response with an initial ILI or ILP. 21 Other therapies such as electrochemotherapy (ECT) and intralesional immunotherapy have also shown promise, although long-term efficacy remains to be determined. 22, 23 The current study is one of few U.S. series evaluating the utility of ILI for advanced extremity melanoma and certainly one of the first to specifically evaluate the effect of surgical resection after ILI and its impact on disease recurrence as well as overall survival. Particularly for patients with continuing development of in-transit disease or multifocal disease, ILI offers an opportunity to provide noninvasive chemotherapy to the limb, with low morbidity and near-zero risk of limb loss. 18 The current treatment approach adopted by our center and Duke University Medical Center for treatment of in-transit melanoma is to offer ILI to patients with multifocal or multiply recurrent lesions. With growing experience in utilizing ILI in the treatment of advanced extremity melanoma, our study suggests that resecting residual disease in patients who have low disease burden after ILI is an effective strategy to optimally control regionally advanced disease in the limb.
Although the mechanism behind this observation remains to be elucidated, it may be related to tumor biology and the tumor response to melphalan and actinomycin D. Isolated limb infusion in patients who then proceed on to have residual disease resected may even be considered as a neoadjuvant treatment strategy, determining whether the tumor biology is aggressive enough to warrant either a systemic approach or further local/regional modalities.
In conclusion, our study found a survival benefit for surgical resection of residual disease after ILI. Resection of residual disease offered equivalent overall survival and potentially improved disease-free survival as those who attained a CR from ILI-alone. This effect was particularly pronounced for patients who achieved a PR with ILI who then underwent surgical resection of residual disease. For appropriate candidates, particularly those who have a clinical response to ILI, surgical resection should be offered, as it may improve outcome.
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